LYCOS RETRIEVER 
Affymetrix
built 658 days ago
"Affymetrix is a pioneer in the life science research market that continues to set the standard in genetic analysis by successfully commercializing its innovations," said Mike Lachman, CEO and president of USB. "The USB and Affymetrix combination drives higher customer value today and opens the door to new and emerging market opportunities for tomorrow."
Source:
Affymetrix is a long-established leader in the use of human genome sequence information for diagnostic tests and research, with an 80 percent share of the market. But its two Bay Area competitors are both field-testing their own versions of a whole genome microarray. Both companies said earlier this year they plan to launch commercial sales by the end of 2003.
Source:
Affymetrix has headquarters in Santa Clara, California with offices worldwide. Today, these arrays are considered the gold standard tool for analyzing complex genetic information and are used by hundreds of pharmaceutical, biotechnology, agrichemical, diagnostics and consumer products companies as well as academic, government and other non-profit research institutes to analyze the relationship between genes and human health.
Source:
Affymetrix, the developer of state-of-the-art technology for acquiring, analyzing and managing complex genetic information for use in biomedical research, has leased the entire building at 4 G Crosby Drive in Beverly. The 2-story, 80,000-square-foot industrial property is located within the Bedford Business Park. The new tenant will be a neighbor with Parametric Technologies, Medisense, and Polaroid Graphic Imaging. -he company intends to move into the space at the end of the year, when the build-out has been completed. The 10-year lease was negotiated by Glenn Rhuda of CRF Partners on behalf of Affymetrix. The owner, Boston Properties, was represented in-house by Joe Howard.
Source:
Affymetrix manufactures arrays monitor the global activities of genes in yeast, Arabidopsis, Drosophila, mice, rats, and humans. In addition, custom expression arrays can be designed for other model organisms, proprietary sequences, or specific subsets of known genes. For human arrays, expressed sequences from databases are collected and clustered into groups of similar sequences. Using clusters as a starting point, sequences are further subdivided into subclusters representing distinct transcripts. This categorization process involves alignment to the human genome, which reveals splicing and polyadenylation variants.
Source:
The next phase of the trial, which will focus on the validity of Affymetrix ' patents, is scheduled to begin on February 11, 2008. The following phase, expected to occur in May or June 2008, will determine whether Illumina's infringement was willful. Affymetrix has ... requested injunctive relief in this case, and will ask that the Court take up this request once the patents are found to be valid.
Source:
MORE ABOUT
Affymetrix